Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium continues to show a significant effect on disability worsening in people with progressive forms of multiple sclerosis (MS), even in those without signs […] The post ECTRIMS 2025: Vidofludimus calcium shows promise against MS appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
Category: Multiple Sclerosis Research
ECTRIMS 2025: Standard Ocrevus dose holds up in PPMS
Increasing the dose of Ocrevus (ocrelizumab) by two- or threefold, depending on a person’s weight, did not provide additional benefit in slowing disability progression compared with the standard regimen in […] The post ECTRIMS 2025: Standard Ocrevus dose holds up in PPMS appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
Why is response to cannabis variable ? It’s in your jeans and pumps…Beat yer to it!
Tweet Many years ago we showed that there was genetic control of entry of cannabinoids into the brains of mice. We linked the trait back to Swiss mice that arrived into the USA in 1926. There were two males and 5 female white mice that arrived at the Rockerfellow Institute in New York. They gave…
ECTRIMS 2025: Long-term benefits seen with Mavenclad use in MS
Most people with relapsing forms of multiple sclerosis (MS) given Mavenclad (cladribine) did not experience confirmed disability progression for at least four years after starting on the approved therapy, according […] The post ECTRIMS 2025: Long-term benefits seen with Mavenclad use in MS appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
Life with MS has given me a new complex to worry about
I’m not sure what age people begin to care about the lives of birds, but I think I’ve reached that point. I’m not quite at the stage where I name […] The post Life with MS has given me a new complex to worry about appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
ECTRIMS 2025: Ocrevus as good as Gilenya for treating MS in children
Children and adolescents living with multiple sclerosis (MS) seem to benefit at least as much — and for some outcomes, significantly more — from Ocrevus (ocrelizumab) as from treatment with […] The post ECTRIMS 2025: Ocrevus as good as Gilenya for treating MS in children appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
Gone
Tweet This week at ECTRIMS 2025 I understand that Biogen did not have a major presence…Have they dumped MS to focus elsewhere. However they have reported a natalizumab v2.0. It is a another humanised antibody. But why bother I wondered what advantage does it have, natalizumab is given at 300mg i.v. every 4 weeks but…
Menopause is not a risk for progression according to MSBase
Tweet I am not commenting on this you may be interested in the take home message. Bridge F, Sanfilippo PG, Zhu C, Skibina O, Nguyen AL, Kalincik T, Buzzard K, Taylor BV, MacIntyre J, Hall LA, Slee M, Macdonell R, Maltby V, Lechner-Scott J, McCombe P, Butzkueven H, van der Walt A, Jokubaitis VG. Menopause…
ECTRIMS 2025: Frexalimab shows long-term benefits for MS patients
Frexalimab, a therapy Sanofi is developing for multiple sclerosis (MS) patients, led to sustained reductions in disease activity in people with relapsing forms of MS over more than two years […] The post ECTRIMS 2025: Frexalimab shows long-term benefits for MS patients appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
ECTRIMS 2025: Ultra-processed foods may fuel disease in early MS
Consuming large amounts of ultra-processed foods (UPF) — products high in additives, artificial ingredients, and extensive processing — is associated with increased disease activity in people with clinically isolated syndrome […] The post ECTRIMS 2025: Ultra-processed foods may fuel disease in early MS appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com